EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use?

被引：12

作者：

Jassem, Jacek ^{[1
]}

Dziadziuszko, Rafal ^{[1
]}

机构：

[1] Med Acad Gdansk, Dept Radiotherapy & Oncol, PL-80211 Gdansk, Poland

来源：

LANCET ONCOLOGY | 2013年 / 14卷 / 10期

关键词：

CELL LUNG-CANCER; 1ST-LINE TREATMENT; OPEN-LABEL; MUTATIONS; ERLOTINIB; CHEMOTHERAPY; MULTICENTER; GEFITINIB; PHASE-3;

D O I：

10.1016/S1470-2045(13)70352-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：916 / 917

页数：2

共 10 条

[1] Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non-Small-Cell Lung Cancer [J].

Bai, Hua ;

Mao, Li ;

Wang, Hang Shu ;

Zhao, Jun ;

Yang, Lu ;

An, Tong Tong ;

Wang, Xin ;

Duan, Chun Jian ;

Wu, Na Mei ;

Guo, Zhi Qing ;

Liu, Yi Xu ;

Liu, Hong Ning ;

Wang, Ye Yu ;

Wang, Jie .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) :2653-2659

[2]

Gerassino MC, 2013, LANCET ONCOL, DOI DOI 10.1016/S1470-2045(13)70310-3

[3] Genotyping and Genomic Profiling of Non-Small-Cell Lung Cancer: Implications for Current and Future Therapies [J].

Li, Tianhong ;

Kung, Hsing-Jien ;

Mack, Philip C. ;

Gandara, David R. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (08) :1039-1049

[4] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].

Lynch, TJ ;

Bell, DW ;

Sordella, R ;

Gurubhagavatula, S ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Haserlat, SM ;

Supko, JG ;

Haluska, FG ;

Louis, DN ;

Christiani, DC ;

Settleman, J ;

Haber, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139

[5] Detection of mutations in EGFR in circulating lung-cancer cells [J].

Maheswaran, Shyamala ;

Sequist, Lecia V. ;

Nagrath, Sunitha ;

Ulkus, Lindsey ;

Brannigan, Brian ;

Collura, Chey V. ;

Inserra, Elizabeth ;

Diederichs, Sven ;

Iafrate, A. John ;

Bell, Daphne W. ;

Digumarthy, Subba ;

Muzikansky, Alona ;

Irimia, Daniel ;

Settleman, Jeffrey ;

Tompkins, Ronald G. ;

Lynch, Thomas J. ;

Toner, Mehmet ;

Haber, Daniel A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (04) :366-377

[6] Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial [J].

Mitsudomi, Tetsuya ;

Morita, Satoshi ;

Yatabe, Yasushi ;

Negoro, Shunichi ;

Okamoto, Isamu ;

Tsurutani, Junji ;

Seto, Takashi ;

Satouchi, Miyako ;

Tada, Hirohito ;

Hirashima, Tomonori ;

Asami, Kazuhiro ;

Katakami, Nobuyuki ;

Takada, Minoru ;

Yoshioka, Hiroshige ;

Shibata, Kazuhiko ;

Kudoh, Shinzoh ;

Shimizu, Eiji ;

Saito, Hiroshi ;

Toyooka, Shinichi ;

Nakagawa, Kazuhiko ;

Fukuoka, Masahiro .

LANCET ONCOLOGY, 2010, 11 (02) :121-128

[7] EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy [J].

Paez, JG ;

Jänne, PA ;

Lee, JC ;

Tracy, S ;

Greulich, H ;

Gabriel, S ;

Herman, P ;

Kaye, FJ ;

Lindeman, N ;

Boggon, TJ ;

Naoki, K ;

Sasaki, H ;

Fujii, Y ;

Eck, MJ ;

Sellers, WR ;

Johnson, BE ;

Meyerson, M .

SCIENCE, 2004, 304 (5676) :1497-1500

[8] Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial [J].

Rosell, Rafael ;

Carcereny, Enric ;

Gervais, Radj ;

Vergnenegre, Alain ;

Massuti, Bartomeu ;

Felip, Enriqueta ;

Palmero, Ramon ;

Garcia-Gomez, Ramon ;

Pallares, Cinta ;

Miguel Sanchez, Jose ;

Porta, Rut ;

Cobo, Manuel ;

Garrido, Pilar ;

Longo, Flavia ;

Moran, Teresa ;

Insa, Amelia ;

De Marinis, Filippo ;

Corre, Romain ;

Bover, Isabel ;

Illiano, Alfonso ;

Dansin, Eric ;

de Castro, Javier ;

Milella, Michele ;

Reguart, Noemi ;

Altavilla, Giuseppe ;

Jimenez, Ulpiano ;

Provencio, Mariano ;

Angel Moreno, Miguel ;

Terrasa, Josefa ;

Munoz-Langa, Jose ;

Valdivia, Javier ;

Isla, Dolores ;

Domine, Manuel ;

Molinier, Olivier ;

Mazieres, Julien ;

Baize, Nathalie ;

Garcia-Campelo, Rosario ;

Robinet, Gilles ;

Rodriguez-Abreu, Delvys ;

Lopez-Vivanco, Guillermo ;

Gebbia, Vittorio ;

Ferrera-Delgado, Lioba ;

Bombaron, Pierre ;

Bernabe, Reyes ;

Bearz, Alessandra ;

Artal, Angel ;

Cortesi, Enrico ;

Rolfo, Christian ;

Sanchez-Ronco, Maria ;

Drozdowskyj, Ana .

LANCET ONCOLOGY, 2012, 13 (03) :239-246

[9] Erlotinib in previously treated non-small-cell lung cancer [J].

Shepherd, FA ;

Pereira, JR ;

Ciuleanu, T ;

Tan, EH ;

Hirsh, V ;

Thongprasert, S ;

Campos, D ;

Maoleekoonpiroj, S ;

Smylie, M ;

Martins, R ;

van Kooten, M ;

Dediu, M ;

Findlay, B ;

Tu, DS ;

Johnston, D ;

Bezjak, A ;

Clark, G ;

Santabárbara, P ;

Seymour, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02) :123-132

[10] Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study [J].

Zhou, Caicun ;

Wu, Yi-Long ;

Chen, Gongyan ;

Feng, Jifeng ;

Liu, Xiao-Qing ;

Wang, Changli ;

Zhang, Shucai ;

Wang, Jie ;

Zhou, Songwen ;

Ren, Shengxiang ;

Lu, Shun ;

Zhang, Li ;

Hu, Chengping ;

Hu, Chunhong ;

Luo, Yi ;

Chen, Lei ;

Ye, Ming ;

Huang, Jianan ;

Zhi, Xiuyi ;

Zhang, Yiping ;

Xiu, Qingyu ;

Ma, Jun ;

Zhang, Li ;

You, Changxuan .

LANCET ONCOLOGY, 2011, 12 (08) :735-742

← 1 →